Sign in
CompletedPhase 2

Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nimes
Where
France1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
30 people enrolled
Started
5 Feb 2024
Ended
5 Mar 2025
Type of study
Interventional
Record updated
21 March 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • A patient with a confirmed DSM-5 diagnosis of severe alcohol use disorder
  • BDI II score (Beck Depression Inventory) ≥ 14
  • The last drink must have been consumed between 60 and 14 days before the inclusion visit
  • The patient must have had at least 1 HDD during the last drinking period
  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is at least 18 years old

Who cannot take part

  • Schizophrenic disorder, or any history of psychotic disorder as judged by the clinician
  • History of hallucinogen use disorders, any use in the past year or > 25 lifetime uses
  • First-degree relative with a diagnosis of psychotic disorder or type 1 bipolar disorder
  • Patients with dementia or severe cognitive impairment
  • Medical conditions that would prevent safe participation in the trial
  • Dependence on cocaine, psychostimulants, opioids or cannabis (last 12 months)
  • Current non-medical use of cocaine, psychostimulants or opioids (past 30 days)
  • Severe ECG anomalies
  • No access to email
  • Insufficient understanding of French to complete questionnaires
  • past or current manic or hypomanic episode
  • Need for antipsychotic treatment that may interfere with psilocybin
  • Suicidal ideation in progress, scripted (as judged by the clinician)
  • High risk of negative emotional or behavioral response based on investigator's clinical judgment
  • Score CIWA-R ≥ 8

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the feasibility of a trial comparing psilocybin with very low-dose psilocybin (control) in alcohol use disorder with depressive symptoms.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
21 March 2024